Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 5Phase 1 3Phase NA 2Phase 1/2 2

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Gastrointestinal 1Breast 1

Conditions

Recurrence 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma 1Breast Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Vitamin B 12 × Clear all
NCT04150042 2026-01-29

SHARON

General Oncology, Inc.

Phase 1 Recruiting
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence

NCT00554827 2020-01-03

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
55 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT01134341 2019-12-18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
34 enrolled
DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡